Skip to Main Content
Contribute Try STAT+ Today

Telehealth companies struggling to stand out in a crowded virtual care market are increasingly leaning on chatbots, online questionnaires, and automated follow-ups to triage patients and trim costs, letting them care for more patients for less money.

Patients seeking on-demand doctors’ visits and quick prescriptions have a growing number of choices, ranging from private companies like Nurx and Ro mainly offering non-emergency care like birth control consultations to behemoths like Amwell tackling primary and urgent care.  Despite a surge of patients seen during the pandemic, many of these virtual care companies still haven’t turned a profit. And in a sea of competitors offering similar services, the money they save through automation could make a difference in their financial success.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment